TOTAL VOLUME:
$134.2b
24H VOL:
$126,590,312
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,439,516,703
404,175
Markets across
30,277
events
MATCHED EVENTS:
2,685
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves Viridian Therapeutics' Veligrotug?
- Polymarket
FDA approves Viridian Therapeutics' Veligrotug? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolved Jun 28, 2026
Closed: Jun 29, 8:00 PM EST
Polymarket
FDA approves Viridian Therapeutics' Veligrotug?
Description
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is June 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Viridian Therapeutics's Veligrotug as a treatment for thyroid eye disease by July 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds on Polymarket reflect aggregated bets from thousands of traders and can differ meaningfully from traditional analyst forecasts or consensus estimates. While analyst reports may rely on clinical trial data, regulatory pathway assessments, and company timelines, prediction markets incorporate real-time information and financial incentives for accuracy. Comparing Polymarket odds to published analyst views on Veligrotug's approval prospects can reveal whether the market is pricing in more optimism or caution than expert consensus. Divergences often highlight emerging data or regulatory signals that analysts have not yet fully incorporated.
On Polymarket, this event is priced as a binary outcome contract where traders buy or sell shares corresponding to approval or non-approval. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The current implied probability reflects the ratio of capital allocated to the approval outcome relative to total liquidity. Prices move continuously as new trades execute, driven by clinical developments, regulatory communications, or shifts in market sentiment. Traders can enter or exit positions at any time before the Jun 30, 2026 resolution deadline, with contract value converging to either 1 or 0 upon final settlement based on FDA decision.
The market is scheduled to resolve on Jun 30, 2026. Resolution is determined by whether the FDA formally approves Veligrotug for its indicated use. The outcome hinges on the FDA's official decision communicated through a formal approval letter, press release, or regulatory filing. Any conditional or accelerated approval pathway would typically be evaluated according to the market's predefined resolution criteria. Traders should monitor FDA announcements, Viridian press releases, and regulatory databases for definitive signals of approval status as the resolution date approaches.
Key catalysts include clinical trial readouts, FDA meeting minutes or feedback letters, and regulatory announcements from Viridian Therapeutics. Positive Phase 3 efficacy or safety data typically strengthens approval odds, while adverse events or manufacturing concerns can weaken them. FDA advisory committee meetings, if scheduled, often trigger sharp price movements. Competitive approvals in the same therapeutic area, changes in regulatory guidance, or delays in the review timeline can also shift market expectations. Industry news, analyst upgrades or downgrades, and company earnings calls may provide additional context that traders incorporate into pricing before the Jun 30, 2026 resolution.
